Pub. Date : 2007 Jul 1
PMID : 17602080
5 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. | Cisplatin | ERCC excision repair 1, endonuclease non-catalytic subunit | Homo sapiens |
| 2 | Excision repair cross-complementing 1 (ERCC1) has been associated with cisplatin resistance. | Cisplatin | ERCC excision repair 1, endonuclease non-catalytic subunit | Homo sapiens |
| 3 | Excision repair cross-complementing 1 (ERCC1) has been associated with cisplatin resistance. | Cisplatin | ERCC excision repair 1, endonuclease non-catalytic subunit | Homo sapiens |
| 4 | We hypothesized that assigning cisplatin based on pretreatment ERCC1 mRNA levels would improve response. | Cisplatin | ERCC excision repair 1, endonuclease non-catalytic subunit | Homo sapiens |
| 5 | CONCLUSION: Assessment of ERCC1 mRNA expression in patient tumor tissue is feasible in the clinical setting and predicts response to docetaxel and cisplatin. | Cisplatin | ERCC excision repair 1, endonuclease non-catalytic subunit | Homo sapiens |